ATC Group: L01FF05 Atezolizumab

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Antineoplastic and immunomodulating agents
2
Antineoplastic agents
3
Monoclonal antibodies and antibody drug conjugates
4
PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
5
L01FF05
Atezolizumab

Active ingredients

Active Ingredient
Description

Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity.

Medicines in this ATC group

Drug
Countries

Australia Austria Brazil Canada Cyprus ...

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)